Home  >  News
International + Font Resize -

Daiichi Sankyo to return development & commercialization rights of thrombus dissolving agent, TS23 to Translational Sciences

Tokyo, Japan
Saturday, December 2, 2017, 11:00 Hrs  [IST]

Daiichi Sankyo Company and Translational Sciences have announced that Daiichi Sankyo will return all rights to develop and commercialize Translational Sciences’ investigational thrombus (blood clot) dissolving agent, TS23, after a successful phase Ia clinical trial.

“Translational Sciences has been an excellent partner,” said Marielle Cohard-Radice, executive vice president, Global Head of Development of Daiichi Sankyo. “Our decision to terminate this agreement is based solely on our efforts to re-prioritize and re-focus our portfolio.”

“While we enjoyed a successful partnership with Daiichi Sankyo, we understand the reprioritization of their portfolio,” said Guy Reed, MD of Translational Sciences. “There is a significant need for a safe, effective therapy for the millions of people who suffer from ischemic stroke, venous thromboembolism and myocardial infarction. After completing a successful Phase Ia trial, we are committed to advancing the clinical development of this novel monoclonal antibody for the benefit of patients with cardiovascular diseases.”  

Daiichi Sankyo took an impaired loss of approximately 2.4 billion yen (20 million US dollars) in the second quarter consolidated financial result for FY2017 (IFRS), reflecting payments made in 2015 to Translational Sciences under the terms of the development agreement.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
duphat_150x60
IPJPI18_150x60en_2018
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |